Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses

As a supplement to our existing U54, we propose that Mount Sinai serve as a coordinating site for aggregating and analyzing demographic, clinical and molecular data from multiple lung cancer studies supported by SeroNet. These studies, from prominent institutions across the country, have been investigating the intersection of lung cancer and SARS-CoV-2 to explore the impact of the combined diseases on patient health, investigate the underlying biology that leads to poor outcomes and understand the effects of lung cancer disease and/or treatments on SARS-CoV-2 vaccination-induced immune responses. To accomplish this goal, we will leverage the considerable expertise and experience of the Mount Sinai Bio-informatics group, led by Joseph Finkelstein, and the data analysis capabilities of our partners at the Vanderbilt Department of Statistics.